<\/p>\n
Etova<\/strong> je etodolac<\/strong> tablety dostupn\u00e9 v 200 mg and 400 mg<\/strong> strengths. Etodolac is a preferential COX-2 NSAID<\/strong> — at therapeutic doses it blocks the inflammation-driving COX-2 enzyme more than the stomach-protective COX-1, giving a modestly gentler GI profile than diclofenac, ibuprofen, or naproxen. The usual adult dose is 200–400 mg twice daily with food<\/strong>. Etova is widely used for osteoarthritis, rheumatoid arthritis, acute musculoskeletal pain, and post-operative pain.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Etova<\/strong> je peror\u00e1ln\u00ed tableta obsahuj\u00edc\u00ed etodolac<\/strong>, a second-generation NSAID marketed by Ipca Laboratories. Etodolac belongs to the pyranocarboxylic-acid class and has a documented 5–10 fold preference for COX-2 over COX-1<\/strong> at clinical doses. This places it between classical non-selective NSAIDs (ibuprofen, diclofenac) and highly selective COX-2 inhibitors (celecoxib), with a generally intermediate risk profile.<\/p>\n Etodolac’s 7-hour half-life allows simple twice-daily dosing, and the preferential COX-2 activity means fewer reports of indigestion, gastritis, and peptic ulcer disease than with non-selective NSAIDs at equivalent anti-inflammatory effect.<\/p>\n Etodolac has preferential COX-2 activity<\/strong> — at therapeutic doses it inhibits the inflammation-driving COX-2 enzyme more than the stomach-protective COX-1. This gives a modestly lower risk of GI ulcers than classical non-selective NSAIDs such as diclofenac, ibuprofen, and naproxen.<\/p>\n The therapeutic chain of events is the same for every NSAID:<\/p>\n Because prostaglandins also protect the stomach lining, regulate kidney blood flow, and influence platelet function, the same mechanism that relieves pain is also responsible for the main NSAID side effects: stomach irritation, fluid retention, high blood pressure, and (in some individuals) kidney stress.<\/p>\n Take with food or milk to reduce GI irritation. Swallow tablets whole with water. Doses should be spaced about 12 hours apart (e.g. 8 a.m. and 8 p.m.). Miss a dose: take it when you remember unless the next is due within 4 hours — then skip.<\/p>\n GI safety — read this before the first dose.<\/strong> Every NSAID, including Etova, carries a real risk of gastritis, peptic ulcer, and upper-GI bleeding. The risk is highest in patients over 65, in those with prior ulcer disease, and in anyone also taking low-dose aspirin, corticosteroids, SSRIs, or anticoagulants. Take Etova s j\u00eddlem<\/em>, use the lowest effective dose for the shortest reasonable time<\/em>, and ask your doctor about co-prescribing a proton pump inhibitor (omeprazole, pantoprazole) if you need it for more than 2–4 weeks.<\/p>\n<\/div>\n All NSAIDs (except low-dose aspirin) carry some increase in the risk of heart attack and stroke, and can worsen heart failure. The risk is dose- and duration-dependent and is generally highest with COX-2 selective agents and with diclofenac. Patients with established ischaemic heart disease, peripheral arterial disease, stroke, or uncontrolled hypertension should use non-selective NSAIDs (ibuprofen or naproxen) at the lowest effective dose, or use paracetamol instead where possible.<\/p>\n NSAIDs reduce renal prostaglandin production, which can cause salt and water retention, raise blood pressure, and — in vulnerable patients — cause acute kidney injury. High-risk groups are the elderly, patients on ACE inhibitors\/ARBs plus diuretics (the “triple whammy”), anyone dehydrated (vomiting, diarrhoea, heat, heavy exercise), and those with pre-existing CKD. Stop the NSAID and seek medical review if you develop reduced urine output, swelling, or unexplained weight gain.<\/p>\n Etova is generally well tolerated at standard doses.<\/p>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
What Is Etova Used For?<\/h2>\n
\n
How Does Etodolac Work?<\/h2>\n
\n
Etova Dosing<\/h2>\n
\n
Who Should Not Take Etova?<\/h2>\n
\n
Kardiovaskul\u00e1rn\u00ed riziko<\/h3>\n
Renal (kidney) safety<\/h3>\n
Side Effects of Etova<\/h2>\n
\n
Etova vs Celecoxib and Ibuprofen<\/h2>\n